Imad Ajjawi
Corporate Officer/Principal chez ABSCI CORPORATION
Profil
Imad Ajjawi is the founder of Denovium, Inc. He currently works as the Vice President-Business Development at Absci Corp.
His education includes an MBA from the University of California San Diego and a doctorate from the University of Nevada.
Postes actifs de Imad Ajjawi
| Sociétés | Poste | Début |
|---|---|---|
| ABSCI CORPORATION | Corporate Officer/Principal | 01/01/2021 |
Denovium, Inc.
 Denovium, Inc. Packaged SoftwareTechnology Services Part of Absci Corp., Denovium, Inc. is an American artificial intelligence company that pioneers novel AI methods to accelerate innovation in biology. Denovium is building an artificial intelligence engine (Denovium EngineTM) capable of interpreting disparate biological data types to answer biology's toughest questions. The company partners with leading biotech and pharma companies in specific areas of focus, including gene discovery, protein engineering, and genomic medicine. The company was founded by Toby H. Richardson, Ariel Schwartz, Imad Ajjawi, and Gregory Hannum, with Toby H. Richardson serving as the CEO since incorporation. Denovium was acquired by Absci Corp. on January 12, 2021 for $4 million. | Fondateur | - |
Formation de Imad Ajjawi
| University of California San Diego | Masters Business Admin |
| University of Nevada | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ABSCI CORPORATION | Health Technology |
| Entreprise privées | 1 |
|---|---|
Denovium, Inc.
Denovium, Inc. Packaged SoftwareTechnology Services Part of Absci Corp., Denovium, Inc. is an American artificial intelligence company that pioneers novel AI methods to accelerate innovation in biology. Denovium is building an artificial intelligence engine (Denovium EngineTM) capable of interpreting disparate biological data types to answer biology's toughest questions. The company partners with leading biotech and pharma companies in specific areas of focus, including gene discovery, protein engineering, and genomic medicine. The company was founded by Toby H. Richardson, Ariel Schwartz, Imad Ajjawi, and Gregory Hannum, with Toby H. Richardson serving as the CEO since incorporation. Denovium was acquired by Absci Corp. on January 12, 2021 for $4 million. | Technology Services |
